Vericel Corporation (VCEL) AI Stock Analysis

Vericel Corporation develops, manufactures, and distributes cellular therapies primarily tailored for sports medicine and severe burn care in the United States. Its core commercial products include MACI, an autologous cellularized scaffold product used for repairing cartilage defects of the knee, and Epicel, a permanent skin replacement humanitarian use device for adult and pediatric deep-dermal or full-thickness burns. The company is also advancing NexoBrid, a biological orphan product in the registration stage designed for eschar removal in deep partial-thickness and full-thickness burns. Headquartered in Cambridge, Massachusetts, the company was originally founded in 1989 as Aastrom Biosciences, Inc.

Between FY2021 and FY2025, Vericel expanded annual revenue from $156.2M to $276.3M, supported by a 5-year CAGR of 17.3%. Gross margin widened steadily over the period, moving from 67.9% in FY2021 to 74.4% in FY2025. After net losses of $7.5M in FY2021 and $16.7M in FY2022, the company turned profitable in FY2024 with net income of $10.4M, rising to $16.5M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $306.3M with an operating margin of 0.6% and a net margin of 7.9%. For the quarter ended June 30, 2026, revenue grew 22.5% year-over-year while earnings rose 18.9%.

As of June 30, 2026, Vericel held $162.5M in cash and short-term investments against total debt of $92.5M, yielding net cash of $69.9M. The balance sheet reflects a current ratio of 5.04 and a debt-to-equity ratio of 0.25 on shareholders' equity of $370.0M. Operating cash flow reached $51.9M in FY2025, supporting capital expenditures of $27.2M and delivering free cash flow of $24.7M. Over five years, the diluted share count increased by 2.0%.

At a share price of $40.13, Vericel carries an enterprise value of $1.92B and a market capitalization of $2.05B. The stock trades at a trailing P/E of 85.4x and a forward P/E of 57.1x, well above the US-listed Healthcare median trailing P/E of 24.6x and forward P/E of 17.3x. Its EV/EBITDA stands at 49.6x compared to the peer median of 12.0x, while price-to-sales is 6.7x versus the peer median of 4.1x. Over the past year, VCEL returned 15.5%, trailing the S&P 500 (SPY) return of 16.8%, and over five years returned -21.0% against an 83.0% gain for SPY.

Wall Street coverage includes 7 Strong Buy ratings and 1 Hold rating, with no Sell recommendations. The mean price target is $59.71, representing a 48.8% upside relative to the last close of $40.13. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $0.52 on revenue of $336.2M, followed by EPS of $0.85 on revenue of $392.9M in FY2027. Vericel beat earnings estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Vericel Corporation (VCEL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VCEL income statement, VCEL balance sheet, VCEL key metrics, VCEL analyst forecast, VCEL chart. See the VCEL stock overview for the latest quote and news.